Printer Friendly

RZN Nutraceuticals receives United States Patent and Trademark Office notice of allowance for proprietary HerbaZorb absorption and delivery.

RZN Nutraceuticals, Inc. (Miami, FL) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has received of a Notice of Allowance from the United States Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb. Two of the firm's most popular product offerings, Arthri-Zen Relief and Migra-Zen Relief PLUS capsules already use the technology in their manufacture. The use of this preparation method ensures the rapid and effective absorption of active ingredients.

"We're very pleased that the United States Patent and Trademark Office has recognized HerbaZorb as a patentable delivery system that allows herbal supplements and functional foods to be absorbed with full potency intact," said Mark Lubin, founder of RZN Nutraceuticals, Inc., and a 25-year veteran biomedical engineer and research scientist in the fields of orthopedics, joint diseases, implantable cardiac devices, materials science and medical chemistry.

Among the proprietary characteristics of HerbaZorb noted in the patent application are that it protects beneficial phytochemicals of herbs and herbal extracts from being digested prior to entering the bloodstream, providing a significant advantage to both producers of herbal products and those who consume them. "The basis for our patent is that our delivery system represents a breakthrough in the field of bioavailability, the process by which active ingredients are delivered to the bloodstream intact, ensuring their maximum usefulness in the body." Mr. Lubin commented.

According to company President Robert Hunt, "It is very satisfying to gain this important recognition for HerbaZorb, especially as we continue making the process available to other manufacturers who want us to prepare their herbal ingredients using this new technology."

Clinical researchers have long studied the role absorption plays in the bioavailability of active ingredients ingested into the body. According to the Physician's Desk Reference, only 10 to 20 percent of vitamins and minerals taken orally in tablet form are actually absorbed into the bloodstream.

"My goal has always been to develop the most effective and natural pain relief formulations possible, which resulted in the family of products," Mr. Lubin stated. "With the advances in absorption offered by HerbaZorb, we can ensure that everyone in the industry using herbal blends can benefit from maximum bioavailability so the active ingredients in them are utilized most fully by the human body."

RZN Nutraceuticals' products are marketed direct to natural accounts, through private label, catalogue sales, practitioner offices, health clubs and on company's website. Future distribution plans include national drug store chains and natural supplement outlets.

RZN Nutraceuticals, Inc.

+1-904-213-8232

www.rznnutra.com
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Aug 1, 2009
Words:434
Previous Article:GENova Biotherapeutics signs collaboration agreement with Bridge Bioresearch.
Next Article:Martek announces settlement of French patent dispute with Capsugel.
Topics:


Related Articles
Vitro Diagnostics receives United States notice of allowance.
Light BioScience receives 'Notice of Allowance' of photomodulation patent.
ScienceBased patents dry eye product.
Proteome Obtains Isobaric Mass Labelling Patent.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters